HilleVax (HLVX) Q1 2025 earnings summary

Executive summary

• Q1 2025 net loss was $6.1 million, a significant improvement from $46.8 million in Q1 2024, due to reduced R&D and G&A expenses after discontinuing HIL-214 in infants and workforce reductions.

• Cash, cash equivalents, and marketable securities totaled $159.5 million as of March 31, 2025, with no products approved for sale and no revenue generated to date.

• Focus remains on developing norovirus vaccine candidates, exploring strategic alternatives, and potential business development activities.

Financial highlights

• Operating expenses decreased to $7.6 million from $49.8 million year-over-year, reflecting lower R&D and G&A costs and no in-process R&D charges in 2025.

• Cash used in operating activities was $12.7 million in Q1 2025, down from $33.0 million in Q1 2024.

• No financing activities in Q1 2025; $15.1 million was raised in Q1 2024 via an at-the-market equity offering.

• Accumulated deficit reached $541.9 million as of March 31, 2025.

• Other income was $1.5 million, down from $3.0 million in the prior year quarter.

Outlook and guidance

• Current cash, cash equivalents, and marketable securities are expected to fund operations for at least the next 12 months.

• No revenue expected until successful development and regulatory approval of vaccine candidates, which is not anticipated for several years, if ever.

• Exploring continued development of norovirus vaccine candidates in adults and considering strategic alternatives.

• Future funding needs will depend on clinical development progress, regulatory outcomes, and potential business development activities.